LINC01194 and neoplasm: Unexpectedly, when using the aberrantly expressed tumor antigen (e.g. HER2) as a model, PD-L1 expression on tumor cells almost completely abolished the tumor suppression by low-affinity single-HER2 targeted CAR-T cells, PD-L1 CCR is able to fully reinvigorate the dual-targeted CAR-T cells to control tumor growth, suggesting that PD-L1 CCR could antagonized PD-L1 inhibition to improve the tumor-lytic activity of CAR-T cells whereas single-HER2-targeted CAR-T cells failed to do so.